

Resource Summary Report

Generated by PRECISE-TBI on Sep 16, 2026

Thermo Fisher: Sartorius: IncuCyte S3 Live Cell Analysis System

RRID:SCR_023147

Type: Tool

Proper Citation

Thermo Fisher: Sartorius: IncuCyte S3 Live Cell Analysis System (RRID:SCR_023147)

Resource Information

URL: <https://www.sartorius.com/en/products/live-cell-imaging-analysis/live-cell-analysis-instruments/s3-live-cell-analysis-instrument#id-797316>

Proper Citation: Thermo Fisher: Sartorius: IncuCyte S3 Live Cell Analysis System (RRID:SCR_023147)

Description: System that automatically captures and analyzes images of living cells around-the-clock for days, weeks, or months, while cells remain undisturbed inside standard tissue culture incubator. Kinetic, image-based measurements. Used for cell monitoring and surveillance, cell health and viability, migration and invasion, phenotypic cell based assays.

Synonyms: Incucyte Live-Cell Analysis System, Incucyte S3 Live-Cell Analysis Instrument, Incucyte S3 System

Resource Type: instrument resource

Keywords: Instrument, Equipment, USEDit, Sartorius AG, living cells images, automatically capture and analyze images,

Resource Name: Thermo Fisher: Sartorius: IncuCyte S3 Live Cell Analysis System

Resource ID: SCR_023147

Record Creation Time: 20230118T050205+0000

Record Last Update: 20260912T200035+0000

Ratings and Alerts

No rating or validation information has been found for Thermo Fisher: Sartorius: IncuCyte S3 Live Cell Analysis System.

No alerts have been found for Thermo Fisher: Sartorius: IncuCyte S3 Live Cell Analysis System.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 77 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#).

Thienger P, et al. (2026) A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degradable Molecules. *Cancer research*, 86(7), 1570.

Aggrey-Fynn JE, et al. (2026) Epigenetic context defines the transcriptional activity of canonical and noncanonical NF- κ B signaling in pancreatic cancer. *Cell death discovery*, 12(1).

Zeng Z, et al. (2026) Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer. *British journal of cancer*, 134(12), 1830.

Mrkacek M, et al. (2026) ORMDL Proteins Turnover via Proteasome and Autophagy Is Cell-Type Dependent and Tied to Ceramide Homeostasis. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 40(6), e71655.

Davi V, et al. (2026) Endoplasmic Reticulum Geometry Dictates Neuronal Bursting via Calcium Store Refill Rates and Exposes Selective Neuronal Vulnerability. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(36), e21101.

Fang C, et al. (2026) Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. *Cancer research*, 86(8), 1956.

Grace E, et al. (2026) Metabolic plasticity and optimal redox homeostasis are essential for efficient metastatic colonization. *Molecular metabolism*, 109, 102382.

Lin P, et al. (2026) CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models. *Blood cancer discovery*, 7(2), 234.

McDonald TO, et al. (2026) BESTDR Enables Bayesian Quantification of Mechanism-Specific Drug Responses. *Cancer research*, 86(5), 1286.

Esapa B, et al. (2026) An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer. *NPJ*

precision oncology, 10(1).

Nigri J, et al. (2026) Myofibroblasts Induce Neuroplasticity to Promote Pancreatic Inflammation and Cancer Progression. *Cancer discovery*, 16(5), 1014.

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. *Cell reports*, 45(5), 117314.

Shah UA, et al. (2026) A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model. *Cancer discovery*, 16(4), 697.

Yapindi L, et al. (2026) Dual Inhibition of TRIP13 and Aurora A Induces Mitotic DNA Damage and Concurrent Pyroptotic-Apoptotic Cell Death in Rb-Deficient Cancer Cells. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(14), 3043.

Li N, et al. (2026) Development of Glypican 3-Targeting Antibody-Drug Conjugates for Hepatocellular Carcinoma Therapy. *Cancer research communications*, 6(7), 1665.

Singh D, et al. (2026) Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity. *Cancer research*, 86(5), 1252.

Burchett R, et al. (2026) A Universal Boosting Strategy for Adoptive T-cell Therapy Using a Paired Vaccine/Chimeric Antigen Receptor. *Cancer immunology research*, 14(2), 261.

Boudjadi S, et al. (2026) Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. *Molecular cancer therapeutics*, 25(3), 493.

Zink A, et al. (2026) Pluripotent stem-cell-based screening uncovers sildenafil as a mitochondrial disease therapy. *Cell*, 189(6), 1656.

Laforêts F, et al. (2026) Matrix structure and microenvironment dynamics correlate with chemotherapy response in ovarian cancer. *iScience*, 29(3), 114858.